Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01757860 · ClinicalTrials.gov registry record · Phase 1
Safety and Pharmacokinetics Study of CARD-024 in Healthy Subjects
A Phase 1 study of Drug Safety and Heart; Disease, Activity, sponsored by Cardiavent.
- Completed
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
- 1
- Study location
NCT01757860 is a Phase 1 study of Drug Safety and Heart; Disease, Activity that has completed, run by Cardiavent. The registered enrollment target is 34 participants, below the 95-participant average among 4 other Drug Safety trials with a reported enrollment target (64% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01757860, a Phase 1 study of Drug Safety and Heart; Disease, Activity, has completed, sponsored by Cardiavent.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
- 1
- Study location
Study Summary
Study Phase: Phase 1 Primary Objective: • To evaluate the safety and tolerability of single ascending oral doses of CARD-024 in healthy subjects Secondary Objectives: * To evaluate the pharmacokinetic (PK) profile of CARD-024 following ascending single oral doses of CARD-024 * To evaluate the effect of CARD-024 on cardiovascular indices including plasma renin activity (PRA) and blood pressure (BP), biological markers of activity, following ascending single oral doses of CARD-024
Conditions Studied
Interventions
- DRUG CARD-024
- OTHER Drug Carrier
Study Locations (1)
Michigan
- Jasper Clinic - Kalamazoo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2011-09 |
| Est. Completion | 2012-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01757860
The ClinicalTrials.gov registry entry for NCT01757860 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 95-participant average among 4 other Drug Safety trials with a reported enrollment target (64% lower). The listed sponsor is Cardiavent, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Drug Safety appearing as the primary indexed condition, and to 2 interventions - of which CARD-024 is the first listed.
NCT01757860 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.
Frequently Asked Questions
What is clinical trial NCT01757860 about?
NCT01757860 is a clinical study titled "Safety and Pharmacokinetics Study of CARD-024 in Healthy Subjects". Study Phase: Phase 1 Primary Objective: • To evaluate the safety and tolerability of single ascending oral doses of CARD-024 in healthy subjects Secondary Objectives: * To evaluate the pharmacokinetic (PK) profile of CARD-024 following ascending single oral doses of CARD-024 * To evaluate the ef...
What is the current status of trial NCT01757860?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2011-09. Estimated completion is 2012-01.
What conditions does trial NCT01757860 study?
This clinical trial studies the following conditions: Drug Safety, Heart; Disease, Activity.
What interventions are being tested in trial NCT01757860?
The interventions under investigation include: CARD-024 (DRUG), Drug Carrier (OTHER).
Who is sponsoring clinical trial NCT01757860?
This trial is sponsored by Cardiavent, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01757860 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Drug Safety
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Clinical Safety of a Novel Milk Protein Peptide
COMPLETED · Phase 1
-
Ascending Multiple-Dose Study to Evaluate VIA-3196 in Healthy Subjects
COMPLETED · Phase 1
-
Reducing and Removing Hyaluronic Acid Filler With Hyaluronidase
ACTIVE NOT RECRUITING · Early Phase 1
-
Comparing Patient Comfort and Safety Between Iodixanol and Iopamidol in Patients Undergoing Peripheral Arteriography
COMPLETED · Phase 4
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.